Psoriatic Arthritis
Conference Coverage
Family history of psoriasis and PsA predicts disease phenotype
Some rheumatologic family history may predict disease phenotype for psoriasis and psoriatic arthritis.
Conference Coverage
Psoriasis duration reflects cardiovascular event risk
For every year of psoriasis, a patient’s risk of a major cardiovascular event climbs an additional 1%.
Conference Coverage
Is PASI 100 the new benchmark in psoriasis?
KAUAI, HAWAII – “I think we should just do away with PASI 90 and look at how well our drugs do against the metric of PASI 100.”
News
MACE risk similar across arthritis subtypes
The older age of patients with rheumatoid arthritis explained most of their elevated risk of major adverse cardiovascular events.
Conference Coverage
How to avoid severe diarrhea from apremilast
Delayed up-titration of apremilast is often effective, albeit at cost of slower efficacy.
News
New PsA questionnaire fails to beat existing early screening methods
New eight-item CONTEST questionnaire matched the accuracy of the five-item PEST questionnaire.
Latest News
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
Anti-TNF alpha antibody biosimilar will enter European markets this year, but won’t be in United States until 2023.
News
Reassurance for women taking certolizumab during pregnancy
Exposure to certolizumab pegol does not appear to be associated with an increased risk of fetal death or congenital malformations.
Audio
MDedge Daily News: Does more marijuana mean fewer opioids?
And acutely ill patients may not get enough venous thromboembolism prophylaxis.
News
Most PsA patients discontinue initial biologic within 12 months
The results “suggest a high frequency of suboptimal biologic experience in patients with PsA.”